Publication:
Correlation between blood telomere length and CD4+ CD8+ T-cell subsets changes 96 weeks after initiation of antiretroviral therapy in HIV-1-positive individuals

dc.contributor.authorChalouni, Mathieu
dc.contributor.authorRodriguez-Centeno, Javier
dc.contributor.authorSamri, Assia
dc.contributor.authorBlanco, Julian
dc.contributor.authorStella-Ascariz, Natalia
dc.contributor.authorWallet, Cedrick
dc.contributor.authorKnobel, Hernando
dc.contributor.authorZucman, David
dc.contributor.authorAutran, Brigitte
dc.contributor.authorThiebaut, Rodolphe
dc.contributor.authorRaffi, François
dc.contributor.authorArribas, José Ramón
dc.contributor.authorAlejos, Belén
dc.contributor.funderRed de Investigación Cooperativa en Investigación en Sida (España)
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
dc.date.accessioned2020-08-10T08:26:11Z
dc.date.available2020-08-10T08:26:11Z
dc.date.issued2020
dc.description.abstractIn 31 participants who started first-line antiretroviral therapy in the NEAT 001/ANRS 143 clinical trial, we found after 96 weeks a statistically significant increase in blood telomere length (TL) of 0.04 (T/S Ratio) (p = 0.03). This increase was positively correlated with both the change in the percentage of CD4+ T-cells and with the decrease of CD38+ molecules on Central Memory CD8+ and negatively correlated with the change in the percentage of CD4+ Effector Memory cells. Increase in TL could be an expression of immune reconstitution and the associated decrease in immune activation. We acknowledge for the low statistical power due to the small sample size and the potential for false positive results due to multiple testing. Hence, further studies are needed to confirm these observations.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThis work was supported by NEAT-ID Foundation (not for profit private foundation to promote research and education projects in the HIV field); Red Temática Cooperativa de Investigación en Sida; and Fondo de Investigaciones Sanitarias (supported by FEDER funds; grant number PI13/01467) The NEAT 001/ANRS 143 trial was supported by Gilead Sciences, Janssen Pharmaceuticals, and Merck Laboratories. French National Institute for Health and Medical Research–France Recherche Nord and Sud Sida- HIV Hepatites (Inserm-ANRS) was the sponsor and a founder of the trial. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of thees_ES
dc.format.number4es_ES
dc.format.pagee0230772es_ES
dc.format.volume15es_ES
dc.identifier.citationPLoS One . 2020 Apr 8;15(4):e0230772.es_ES
dc.identifier.doi10.1371/journal.pone.0230772es_ES
dc.identifier.e-issn1932-6203es_ES
dc.identifier.journalPloS onees_ES
dc.identifier.pubmedID32267847es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/10857
dc.language.isoenges_ES
dc.publisherPublic Library of Science (PLOS)
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/PI13/01467es_ES
dc.relation.publisherversionhttps://doi.org/10.1371/journal.pone.0230772es_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemiología (CNE)es_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshADP-ribosyl Cyclase 1es_ES
dc.subject.meshAdultes_ES
dc.subject.meshAnti-Retroviral Agentses_ES
dc.subject.meshAntiretroviral Therapy, Highly Activees_ES
dc.subject.meshCD4 Lymphocyte Countes_ES
dc.subject.meshCD4-Positive T-Lymphocyteses_ES
dc.subject.meshCD8-Positive T-Lymphocyteses_ES
dc.subject.meshFemalees_ES
dc.subject.meshHIV Infectionses_ES
dc.subject.meshHIV Seropositivityes_ES
dc.subject.meshHIV-1es_ES
dc.subject.meshHumanses_ES
dc.subject.meshImmunologic Memoryes_ES
dc.subject.meshImmunophenotypinges_ES
dc.subject.meshLymphocyte Activationes_ES
dc.subject.meshMalees_ES
dc.subject.meshMiddle Agedes_ES
dc.subject.meshT-Lymphocyte Subsetses_ES
dc.subject.meshTelomerees_ES
dc.subject.meshViral Loades_ES
dc.titleCorrelation between blood telomere length and CD4+ CD8+ T-cell subsets changes 96 weeks after initiation of antiretroviral therapy in HIV-1-positive individualses_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublicationc4102a32-971d-46aa-a2e9-c204117368c1
relation.isAuthorOfPublication.latestForDiscoveryc4102a32-971d-46aa-a2e9-c204117368c1
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublicationefa64f05-b985-4984-8f1e-5fc4ef21f502
relation.isFunderOfPublication.latestForDiscovery7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isPublisherOfPublicationa2759e3d-0d58-4e8a-9fcd-c6130ee333d1
relation.isPublisherOfPublication.latestForDiscoverya2759e3d-0d58-4e8a-9fcd-c6130ee333d1

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
CorrelationBetweenBloodTelomere_2020'.pdf
Size:
489.87 KB
Format:
Adobe Portable Document Format
Description: